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Abstract
Background: Genetic factors and a dysregulated immune response towards commensal bacteria
contribute to the pathogenesis of Inflammatory Bowel Disease (IBD). Animal models demonstrated
that the normal intestinal flora is crucial for the development of intestinal inflammation. However,
due to the complexity of the intestinal flora, it has been difficult to design experiments for detection
of proinflammatory bacterial antigen(s) involved in the pathogenesis of the disease. Several studies
indicated a potential association of E. coli with IBD. In addition, T cell clones of IBD patients were
shown to cross react towards antigens from different enteric bacterial species and thus likely
responded to conserved bacterial antigens. We therefore chose highly conserved E. coli proteins
as candidate antigens for abnormal T cell responses in IBD and used high-throughput techniques
for cloning, expression and purification under native conditions of a set of 271 conserved E. coli
proteins for downstream immunologic studies.
Results: As a standardized procedure, genes were PCR amplified and cloned into the expression
vector pQTEV2 in order to express proteins N-terminally fused to a seven-histidine-tag. Initial
small-scale expression and purification under native conditions by metal chelate affinity
chromatography indicated that the vast majority of target proteins were purified in high yields.
Targets that revealed low yields after purification probably due to weak solubility were shuttled
into Gateway (Invitrogen) destination vectors in order to enhance solubility by N-terminal fusion
of maltose binding protein (MBP), N-utilizing substance A (NusA), or glutathione S-transferase
(GST) to the target protein. In addition, recombinant proteins were treated with polymyxin B
coated magnetic beads in order to remove lipopolysaccharide (LPS). Thus, 73% of the targeted
proteins could be expressed and purified in large-scale to give soluble proteins in the range of 500
μg.
Conclusion:  Here, we report a cost-efficient procedure to produce around 200 soluble
recombinant E. coli proteins in large-scale, including removal of LPS by polymyxin B coated beads
for subsequent use of the proteins in downstream immunological studies.
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Background
Inflammatory Bowel Disease (IBD) comprises Crohn's
disease (CD) and ulcerative colitis (UC). CD is character-
ized by chronic granulomatous inflammation throughout
the entire gastrointestinal tract, with the terminal ileum
mainly affected. In UC, chronic inflammation is limited
to the colorectum, continuous and without granuloma
formation [1]. So far, the etiology of IBD is not fully
understood. Genetic factors, environmental factors and a
dysregulated immune response towards commensal bac-
teria contribute to the pathogenesis [1].
In CD, exposition of the mucosal immune system to the
intestinal flora may result in the production of proinflam-
matory cytokines [2]. Most animal models of IBD are
characterized by increased T helper 1 (Th1) cytokine pro-
duction [3]. Interferon-γ (IFN-γ) was shown to be causa-
tively involved in experimental IBD [4]. In animal models
of IBD, the normal enteric bacterial flora plays a key role
in the development of the disease [1,3,5]. DNA of E. coli
was detected in 80% of CD granulomas by Laser Capture
Microdissection and PCR [6]. Another study demon-
strated the presence of E. coli, Listeria, and Streptococcus
antigens within macrophages of CD patients by immuno-
histochemistry [7]. E. coli is predominant in ileal mucosa
[8,9]. In addition, an adherent-invasive E. coli (AIEC)
strain was isolated from a chronic lesion of a CD patient.
AIEC survived and replicated in the host cell cytoplasm
after lysis of the endocytic vacuole [10] and were shown
to survive and replicate within macrophages [11]. AIEC
are associated with inflammatory lesions of CD patients
[12]. Finally, Gram-negative bacteria, i.e E. coli, were
shown to aggravate Th1 type immunopathology in an ani-
mal model for small intestinal inflammation [13].
In IBD, Duchmann et al. demonstrated T cell reactivity
towards bacterial antigens shared by different Enterobacte-
riaceae, including E. coli [14]. Thus, conserved antigens of
intestinal bacteria could drive chronic inflammation
directly or via induction of autoimmunity. Therefore, we
aimed at a systematical study of a potential role of con-
served E. coli proteins in the pathogenesis of IBD.
The most conserved protein functions are represented in
all three biological kingdoms, Archaea, Prokarya, and
Eukarya. Thus, we first chose a set of E. coli proteins hypo-
thetically inherited by the Last Universal Common Ances-
tor (LUCA) [15] of the three kingdoms. As a second set we
identified additional conserved proteins between E. coli
and humans that were not included in the LUCA set of
proteins. In general, these highly conserved proteins are
not represented in Archaea and therefore not included in
the LUCA proteins. These proteins are referred to as E. coli-
Human-Homologues (ECHH). Since most of the highly
conserved protein functions addressed in this study also
are represented in humans, T cell reactivity towards these
proteins could give a hint to potentially autoreactive
human antigens in IBD.
In this project, we aimed at the production of purified
ECHH and LUCA proteins represented in E. coli at
amounts of around 500 μg, suitable for downstream
whole blood T cell stimulation assays.
Cloning steps such as amplification of target genes with
polymerase chain reaction (PCR), DNA purification,
digestion of target genes with restriction enzymes, vector
ligation, and transformation of chemically competent E.
coli cells were performed in a 96-well microtitre plate for-
mat. In order to identify clones that provided sufficient
amounts of proteins, a high-throughput purification
method using a pipetting robot was applied as recently
established in the Protein Structure Factory [16]. Initially,
clones were subjected to small-scale expression. Histidine-
tagged (His-tag) proteins were purified under native con-
ditions  via  affinity chromatography to a nickel chelate
matrix. After cell lysis, soluble proteins were expected to
bind to the matrix. Elution of bound proteins into a dena-
turing buffer and SDS-PAGE analysis identified proteins
that were purified in sufficient yields. Suitable expression
clones were then used for large-scale protein expression
and purification to obtain a minimum of 500 μg per pro-
tein for downstream immunological studies. During lysis
of bacterial cells, lipopolysaccharide (LPS), a component
of the outer membrane of Gram-negative bacteria, can be
released. LPS is a strong activator of the innate immune
system via Toll-like receptor 4 (TLR-4) [17]. Since LPS
could interfere with downstream immunological applica-
tions [18-20], such as in vitro stimulation of whole blood
or peripheral blood mononuclear cells (PBMCs), we
decided to include a step for LPS removal in the protocol
for large-scale production of proteins. A variety of ligands
has been used for removal of LPS [21], including poly-
myxin B which was shown to neutralize LPS activity in
PBMCs [22]. To remove LPS from protein solutions, we
used a rapid, automatable procedure based on polymyxin
B coated magnetic beads.
Herein, we report on cloning, large-scale expression and
purification of 197 of the most conserved E. coli proteins.
Results
LUCA proteins
We were able to identify in the E. coli K12 genome 223 of
246 LUCA proteins described by Kyrpides et al. [15](see
additional file 1: SummaryOfResults.xls). Of 223 LUCA
genes represented in E. coli, we successfully cloned 221
(99.1%) into pQTEV2 (Fig 1). In small-scale, expression
of 209 His-tagged proteins (94.6%) was detected in the
cell extracts. Of these 209 proteins, 5 proteins could notMicrobial Cell Factories 2007, 6:18 http://www.microbialcellfactories.com/content/6/1/18
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be purified under native conditions with Ni-NTA agarose
(proteins 198, 199, 205, 208, 209). 204 proteins (97.6%)
could be purified. To obtain maximum amounts of pro-
tein, 161 proteins were expressed at 37°C and 43 proteins
at 25°C (data not shown). 111 proteins (54.4%) were
purified in high yields, 66 (32.4%) in moderate, and 27
(13.2%) in low yields. The estimation of protein yields is
illustrated in Fig. 2. Together with the genes coding for the
5 proteins that were not purified, the genes of 27 proteins
with low yields were subjected to Gateway (Invitrogen)
recombination cloning in order to improve solubility by
fusing the target proteins to MBP-His7, GST-His7, and
NusA-His6.
ECHH proteins
Of 48 ECHH genes, we successfully cloned 47 (97.9%)
into pQTEV2 (Fig 3). Expression of 45 His-tagged proteins
(95.7%) was detected in the bacterial lysate. To obtain
maximum amounts of protein, 40 proteins were
expressed at 37°C and 5 proteins at 25°C (data not
shown). All of these 45 proteins could be purified with
Ni-NTA agarose. 36 proteins (80%) were purified in high
yields, 7 (15.5%) in moderate, and two (4.5%) in low
yields. These two genes were also subjected to Gateway
recombination cloning.
In total, 14 LUCA or ECHH proteins could not be
expressed in E. coli SCS1 (see additional file 1: Summary-
OfResults.xls). Some proteins could not be expressed at
all. Other proteins could be expressed, but revealed low
yields in small-scale purification or could not be purified.
The distribution of these proteins into functional groups
is illustrated in Table 1. Interestingly, 53% of transport
proteins present in either protein sets were not expressed.
33% of ribosomal proteins were purified with low yields.
187 enzymes (87.4%), 15 ribosomal proteins (62.5%),
but only 3 transport proteins (21.4%) were purified in
soluble form with at least moderate yields.
Gateway cloning
Corresponding genes of the 34 proteins that were not
purified or displayed low yields under native conditions
were sub-cloned into Gateway destination vectors in order
to fuse the target proteins to MBP-His7, GST-His7, and
NusA-His6, respectively. The resulting 102 fusion proteins
were overexpressed in small-scale and purified by His-tag
affinity to Ni-NTA agarose. Per target protein, the fusion
partner was determined that most efficiently improved
the yield after purification. Table 2 illustrates yields of 34
target proteins fused to the His7-tag and to MBP-His7,
GST-His7, or NusA-His6. Yields of 30 target proteins
improved with fusion to MBP-His7 (80%), NusA-His6
(16.7%) or GST-His7 (3.3%). Yields of 4 proteins includ-
ing two membrane proteins were not affected.
SDS-PAGE analysis of cell extracts after lysis of bacteria and  purified proteins Figure 2
SDS-PAGE analysis of cell extracts after lysis of bac-
teria and purified proteins. Cell lysates (C) and purified 
proteins (P) were mixed with 4xSDS-PAGE sample buffer. 
Protein bands were visualized by Coomassie staining. Yields 
of purified proteins were classified as indicated with the num-
bers below the protein bands (3: high, 2: moderate1: low). 
Numbers on top of the panel designate proteins as given in 
additional file 1. Note that only one clone per protein was 
chosen for large-scale purification.
3          3         3          2         2         2         2  1
M CCCCCCC CP P P P P P P P
28.2 25.1 25.2 23.1 23.2 30.1 30.2 32.1
Step-by-step efficiency of cloning, small-scale protein expres- sion and purification of E. coliLUCA proteins Figure 1
Step-by-step efficiency of cloning, small-scale protein 
expression and purification of E. coliLUCA proteins. 
177 purified proteins with high and moderate yields were 
subjected to large-scale expression. 142 proteins could be 
purified with a minimum of 500 μg. 32 target genes were sub-
jected to Gateway recombination cloning in order to express 
fusion proteins with MBP-His7, GST-His7, and NusA-His6, 
respectively. Large-scale expression revealed 19 purified pro-
teins fused to MBP-His7 with a minimum of 500 μg.
LUCA proteins: 246 LUCA proteins
of E. coli K12 : 223
Successfully cloned genes: 221 
99.1%
Successfully expressed proteins: 209
94.6%
Successfully purified: 204
97.6%
Gateway large-scale large-scale
142 proteins 19 proteins
high: 111 moderate: 66 low: 27 not purified: 5
Yield (small-scale)Microbial Cell Factories 2007, 6:18 http://www.microbialcellfactories.com/content/6/1/18
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LPS removal
Four E. coli proteins were treated with polymyxin B coated
magnetic beads in order to analyze efficiency of this pro-
tocol to reduce potential LPS related stimulation of CD4+
T cells. We compared the frequencies of CD40L+/IFN-γ+ T
cells resulting from whole blood stimulations with pro-
tein solutions before vs. after treatment with polymyxin B
beads. Equal amounts of proteins were applied, i.e. 5 μg
per ml blood. Treatment of proteins 98, 251, and 256
with LPS removal beads reduced the frequency of stimu-
lated CD4+ T cells. Except for protein 98, analyzed in
blood of donor M, all donors showed decreased frequen-
cies. Especially, stimulations with protein 256 revealed a
drastic decrease in all donors. In contrast, treatment of
protein 253 with LPS removal beads did not reduce the
frequency of stimulated CD4+ T cells. In donor M, the fre-
quency of double-positive cells stimulated with protein
253 even increased (Fig 4A). Since we observed variable
loss of protein after incubation with LPS removal beads,
different volumes of protein solutions had to be taken in
subsequent immunological assays to provide 5 μg of pro-
tein per assay. This may have increased the amount of
other stimulatory bacterial contaminants, such as
muramyl dipeptide [23] and lipoproteins [24]. Therefore,
an additional analysis of the frequencies after stimulation
with equal volumes of treated vs. untreated protein solu-
tions was done (Fig. 4B). Without exception, treatment
with LPS removal beads resulted in decreased frequencies.
In addition, LPS contents of protein solutions 251 and 96
were quantified with the Limulus amoebocyte lysate (LAL)
test. Both protein solutions were treated with LPS removal
beads. The LPS content in the protein solution 96 was
below the detection limit of 0.05 EU/ml (5 pg/ml),
whereas 0.08 EU/ml (8 pg/ml) was measured in protein
solution 251.
Next, we quantified protein loss by the LPS removal pro-
cedure. For this, protein concentrations of 34 different
protein preparations were determined before and after
treatment with LPS removal beads. More than 61% of the
analyzed proteins revealed a protein loss less than 50%.
Only 5.9% of the proteins revealed a protein loss of 80–
90% (Table 3). Since only few proteins showed major loss
by the LPS removal procedure, we applied the procedure
to all protein preparations of this study.
Large-scale expression and purification
In order to produce a minimum of 500 μg of purified sol-
uble protein, expression culture volumes were scaled up.
Table 1: Distribution of "difficult" LUCA and ECHH proteins among functional groups of proteins
enzymes (including putative) (214) ribosomal proteins (24) transport proteins (14) putative structure proteins (3)
not expressed 6 - 8 -
not purified 3 1 1 -
purified in low yields 18 8 2 1
Of 268 LUCA and ECHH proteins, 14 proteins were not expressed in small-scale. 34 proteins were expressed. 5 of those proteins could not be 
purified and 29 were purified in low yields. Numbers in brackets give the total number of proteins in respective functional group. Note that all 14 
non-expressed proteins contain at least 2 transmembrane helices.
Step-by-step efficiency of cloning, small-scale protein expres- sion and purification of ECHH proteins Figure 3
Step-by-step efficiency of cloning, small-scale protein 
expression and purification of ECHH proteins. 43 
purified proteins with high and moderate yields were sub-
jected to large-scale expression. 34 proteins could be puri-
fied with a minimum of 500 μg. Two target proteins were 
subjected to Gateway recombination cloning in order to 
express fusion proteins with MBP-His7, GST-His7, and NusA-
His6, respectively. Both proteins fused to MBP-His7 were 
purified with a minimum of 500 μg.
Successfully cloned genes: 47
97.9%
Successfully expressed proteins: 45
95.7%
Successfully purified: 45
100%
ECHH proteins
of E. coli K12: 48
34 proteins
large-scale
2 proteins
Gateway large-scale
Yield (small-scale)
high: 36 moderate: 7 low: 2Microbial Cell Factories 2007, 6:18 http://www.microbialcellfactories.com/content/6/1/18
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By small-scale expression and purification, we obtained
177 LUCA proteins with high and moderate yields (Fig 1).
However, in 35 proteins we did not achieve the minimum
of 500 μg of purified protein. 26 of 32 Gateway LUCA
fusion proteins revealed high or moderate yields when
expressed in small-scale. Of these, 19 were expressed and
purified in large-scale as fusions to MBP-His7 (Fig 1). Of
43 ECHH proteins with high and moderate yields when
expressed in small-scale, 9 proteins could not be produced
in sufficient amounts. In addition, we obtained 2 ECHH
proteins from Gateway fusions to MBP-His7. Thus, we
were able to produce 36 ECHH proteins with a minimum
of 500 μg (Fig 3).
Codon usage
In order to correlate codon usage of proteins with success
of expression, the codon adaptation index (CAI)[25], a
global indicator which compares codon usage of individ-
ual proteins with codon usage of a set of reference pro-
teins, was determined for all proteins. As shown in Fig
5A., all proteins with a CAI of > 0.6 could be over-
expressed in our system. In addition, we studied individ-
ual codons most rarely used in E. coli in a representative
set of proteins. This analysis revealed that some rare
codons are overrepresented in non-expressed proteins
(Fig 5B.). Of particular interest might be the rare isoleu-
cine codon ATA which occured 3 times or 15 times more
frequently in non-expressed proteins than in weakly or
highly expressed proteins, respectively (Fig 5B).
Transmembrane helices
The 48 proteins that could not be expressed or yielded no
protein or insufficient quantities of protein after purifica-
tion as non-fusion proteins (see Table 1) were subjected
to an in-silico analysis for the presence of predicted trans-
membrane domains. In addition, an arbitrarily chosen
Table 2: Gateway recombination cloning of 34 LUCA and ECHH genes
No. Protein Yield with His7-tag Fusion with Yield
157 aspartokinase I; homoserine dehydrogenase I 1 MBP 3
145 acetolactate synthase III small subunit 1 MBP 3
203 thiogalactoside acetyltransferase 1 MBP 2
200 4-hydroxy-2-ketovalerate aldolase 1 MBP 2
258 putative ATPase 1 MBP 3
204 anthranilate synthase component II 1 MBP 2
155 putative ATP-binding component of a transport system 1 MBP 3
201 flagellum-specific ATP synthase 1 MBP 2
259 fused enoyl-CoA hydratase and epimerase 1 MBP 2
156 FFh 1M B P 2
146 30S ribosomal subunit protein S11 1 MBP 2
147 30S ribosomal subunit protein S13 1 MBP 3
148 50S ribosomal subunit protein L14 1 MBP 3
149 50S ribosomal subunit protein L22 1 MBP 3
151 50S ribosomal subunit protein L23 1 MBP 2
152 30S ribosomal subunit protein S12 1 MBP 2
150 50S ribosomal subunit protein L2 1 MBP 3
154 50S ribosomal subunit protein L1 1 MBP 3
153 biotin- [acetyl-CoA carboxylase] holoenzyme synthetase 1 MBP 3
159 RNA polymerase beta prime subunit 1 MBP 2
143 predicted acyltransferase with acyl-CoA N-acyltransferase 1 MBP 3
144 putative proteoglycan 1 MBP 2
158 endonuclease III 1 MBP 2
161 dihydroxyacid dehydratase 1 MBP 3
202 part of formate-dependent nitrite reductase complex 1 NusA 2
206 conserved protein, member of DEAD box family 1 NusA 2
198 50S ribosomal subunit protein L5 0 NusA 2
205 O-6-alkylguanine-DNA/cysteine-protein methyltransferase 0 NusA 1
199 acetylornithine delta-aminotransferase 0 NusA 1
197 inducible ATP-independent RNA helicase 1 GST 2
160 glutamate synthase large subunit 1 -
207 carbamoyl-phosphate synthase large subunit 1 -
208 ATP-binding transport protein (membrane protein) 0 -
209 Mg2+ transport ATPase, P-type 1 (membrane protein) 0 -
Yields of purified proteins were analyzed by SDS-PAGE before recombination (proteins fused to His7-tag) and after recombination (each target 
protein fused to MBP-His7, GST-His7, or NusA-His6, respectively). The fusion partner that most efficiently improved protein yield is shown. With 
regard to yield, proteins were attributed to one of four categories: 3 (high), 2 (moderate), 1 (low), 0 (not purified).Microbial Cell Factories 2007, 6:18 http://www.microbialcellfactories.com/content/6/1/18
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protein was included in this study. The results of this anal-
ysis are given in the additional file 1 (SummaryOfRe-
sults.xls). All 14 non-expressed proteins contained at least
2 predicted transmembrane helices (proteins 210–221,
269, 270). The two proteins that could be expressed but
not be purified even as fusion proteins contained 5 or 7
predicted transmembrane helices, respectively (proteins
208, 209). On the other hand, at least 3 proteins contain-
ing 1, 2, or 8 predicted transmembrane helices, respec-
tively, could be expressed and purified in sufficient
quantities using our approach (proteins 202, 163, 258).
Discussion
Our aim was the homologous expression and purification
of a large number of the most conserved E. coli proteins.
We aimed at producing a minimum amount of 500 μg per
protein for downstream immunological studies. For this,
we cloned target genes into the expression vector pQTEV2,
Codon usage Figure 5
Codon usage. A. Global analysis: The codon adaptation 
index (CAI) was determined for each protein, sorted by the 
level of expression. B. Analysis of 6 individual rare codons. 52 
poteins were included: All 14 non-expressing proteins, all 10 
proteins of low expression level, and a random choice of 14 
proteins each of moderately and highly expressed proteins. 
The graph gives codon frequencies for each of the six codons 
in the total of codons in proteins of identical level of expres-
sion (no of codon X/total no of codons in proteins of expres-
sion group).
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Effect of LPS removal procedure on T cell stimulation Figure 4
Effect of LPS removal procedure on T cell stimula-
tion. A. Equal amounts of proteins: Four proteins were 
treated with LPS removal beads. Whole blood of 3 healthy 
donors was stimulated with 5 μg/ml of treated or non-
treated protein preparations. After fixation and permeabiliza-
tion, leukocytes were stained with antibodies against CD4, 
CD40L, and IFN-γ. The stained cells were measured by 
FACS. CD4+ T cells were gated electronically. Frequencies 
of double-positive T cells stimulated with treated prepara-
tions were related to frequencies obtained after stimulation 
with untreated proteins. The latter frequencies were stand-
ardized (set to 100%). B. Equal volumes: The results of the 
experiment given in A. are displayed considering equal vol-
umes of treated and untreated protein preparations, respec-
tively. Representative results from 3 of 8 individuals tested.
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Table 3: Protein recovery of 34 E. coli proteins after incubation 
with LPS removal beads
Protein recovery (%) Number of proteins
10 – 20 2
21 – 50 11
51 – 90 7
> 90 14
After treatment with LPS removal beads, protein recovery was 
determined and related to protein content before treatment (in %).Microbial Cell Factories 2007, 6:18 http://www.microbialcellfactories.com/content/6/1/18
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which provides a His7-tag. Overexpression and purifica-
tion by nickel affinity chromatography was performed in
small-scale in order to identify the clones that yielded sol-
uble proteins. Proteins that were not purified or revealed
low yields were fused to fusion partners to enhance solu-
bility (Gateway recombination cloning). We successfully
amplified 99% of the target genes. Our amplification
results confirm recently published data targeting bacterial
genes [26-28]. Our PCR products were digested with
BamHI and NotI or alternative enzymes in a few cases. All
PCR products were successfully cloned into the expression
vector pQTEV2. Subsequently, 94% of the selected E. coli
proteins could be expressed as His7-tag fusions in small-
scale. The rate of expressed proteins was as described [27].
Small-scale expression of the E. coli proteins showed that
87% of the selected E. coli proteins were expressed as His6-
tag fusions using the Gateway system [27]. In this study,
different E. coli host strains were used in order to optimize
expression efficiency. Proteins of the eukaryotic organism
Caenorhabditis elegans were also expressed in E. coli.
10,167 ORFs were cloned into a Gateway vector. Two dif-
ferent strains were used as hosts. However, only 48% of
the proteins could be expressed in small-scale [29]. In
experiments where human proteins were expressed in E.
coli, only 16% of these proteins were expressed in soluble
form [30]. Similar results were obtained with C. elegans
proteins: 15% of the selected proteins were soluble [29].
Small numbers of soluble eukaryotic proteins are not sur-
prising and could reflect problems with different codon
usage or lacking posttranslational modifications in E. coli.
In small-scale, 92% of our conserved E. coli proteins were
found to be expressed in soluble form in the host cell. This
high rate may result from our selection of highly con-
served proteins. In a different set of E. coli proteins, only
60% of target proteins were expressed in soluble form
[27]. A similar observation was made with soluble expres-
sion of B. anthracis proteins in E. coli with 86% of con-
served proteins but only 69% of non-conserved proteins
[31]. Our strategy to clone target genes with standard
molecular techniques into pQTEV2 in order to generate
His7-tagged proteins in the E. coli host strain SCS1,
revealed a large number of purified proteins. In cases
where proteins were purified with low yields or were not
purified, we utilized the Gateway recombination technol-
ogy in order to fuse these proteins with MBP-His7, GST-
His7, or NusA-His6. Fusion of target proteins to these part-
ners was expected to improve solubility [32]. Indeed, with
regard to our E. coli proteins, yields of most target proteins
improved when fused to MBP-His7 (Table 2). This finding
confirms data on 6 target proteins of various origins [33].
Shih et al. [34] found that 60% of analyzed eukaryotic
proteins were expressed in soluble form when fused to
MBP or NusA. 38% of the target proteins were expressed
in soluble form when fused to GST. In our study, GST and
NusA were less efficient in improving the yields of puri-
fied proteins. This could be due to the different sets of pro-
teins studied (eukaryotic vs. prokaryotic proteins).
Small-scale expression was performed with two clones per
transformation. Using this strategy, we could determine a
minimum of one clone per transformation that expressed
protein, except for 18 genes. In the latter cases, we tested
additional two clones for protein expression and tried
small-scale purification of soluble protein. This approach
enabled us to identify two more proteins expressed in sol-
uble form. Concerning the remaining 16 proteins, we
repeated the cloning procedure, starting with PCR of tar-
get genes. After the second round of cloning, again two
more proteins expressed in soluble form were identified.
Finally, 14 proteins could not be expressed, even after a
third round of cloning and expression. These proteins
consisted of membrane proteins containing at least two
transmembrane helices. Overexpression and purification
of membrane proteins was reported to be difficult [35].
Due to potential formation of inclusion bodies, purifica-
tion under native conditions may not be the appropriate
method for these proteins. Instead, purification under
denaturing conditions might result in sufficient protein
yields in a view of these proteins. Furthermore, non-
expressing proteins showed higher frequencies of rare
codons. Therefore, a number of the proteins that failed to
be expressed in our system could possibly be made in host
strains overexpressing rare t-RNAs. Alternatively, such rare
codons could be mutated in order to increase efficiency of
expression.
During growth, division, and lysis of E. coli cells, LPS is
released [21]. Because the proteins were produced for
immunological assays, such as whole blood stimulations,
the removal of LPS was an important task. At neutrality,
LPS is negatively charged. One potent LPS ligand is poly-
myxin B. At low ionic strength, it is positively charged at
the amino groups. Polymyxin B binds LPS mainly through
hydrophobic interactions with Lipid A and electrostatic
interactions. Electrostatic interactions between the nega-
tively charged LPS and polymyxin B are supposed to be
stronger than between proteins and polymyxin B. In addi-
tion, charged and hydrophobic groups are fixed in pro-
teins due to their globular structure. Still, binding of
negatively charged proteins to polymyxin B is possible,
thus causing protein loss [21]. Analysis of whole blood
stimulations showed that polymyxin B treated proteins
revealed less background stimulation of CD4+ T cells,
compared with equal amounts of untreated proteins (Fig.
4A). When equal volumes of treated or untreated proteins
were analyzed, reduced backgrounds were observed (Fig.
4B). Provided that the proteins did not elicit antigen-spe-
cific T cell responses, this reducing effect may have been
due to removal of LPS. Otherwise, this may reflect less
stimulatory effect by the proteins because of their dilu-Microbial Cell Factories 2007, 6:18 http://www.microbialcellfactories.com/content/6/1/18
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tion. Either way, it is most likely that other bacterial con-
taminants did not have a major stimulatory influence. In
order to determine LPS concentrations in two protein
solutions that were treated with LPS removal beads, the
LAL test was performed. Both protein solutions contained
less than 9 pg/ml LPS. Nakagawa et al. [36] stimulated
whole blood with endotoxin (LPS) in order to determine
the minimum amount of LPS to induce cytokine secretion
in monocytes. The determined detection limit for both,
TNF-α and IL-6 secretion was 14 pg/ml, whereas a mini-
mum LPS concentration of 100 pg/ml was required to
detect LPS-induced IL-1 secretion. Clearly, LPS concentra-
tions of both protein solutions were below these critical
concentrations.
In the large-scale expression procedure, we observed that
52 proteins were not recovered as expected, although
small-scale expression and purification indicated moder-
ate or high yields. Precipitation was often observed imme-
diately after affinity chromatography of these proteins.
This was not observed in small-scale purification, since
the proteins were solubilized directly after elution with
4xSDS sample buffer, whereas in large-scale purifications,
proteins were subjected to additional purification steps,
i.e. buffer exchange and LPS removal. In addition, precip-
itation may be explained by higher concentrations of pro-
teins in large-scale preparations.
Conclusion
Taken together, we obtained 73% of the selected E. coli
proteins with sufficient amounts after purification. Our
strategy combining standard restriction cloning with the
Gateway recombination system proved to be a reliable
and efficient approach to achieve our aim.
Methods
Identification of E. coli K12 targets
E. coli K12 representatives of the LUCA protein functions
as described by Kyrpides et al. [15] were identified in the
NCBI protein database. In addition, the protein databases
Biocyc.org and Brenda were screened for LUCA proteins
present in the E. coli genome. Moreover, the 246 LUCA
proteins represented in M. jannaschii were used as queries
in BlastP searches against the E. coli K12 protein
sequences. By these methods, we identified 223 LUCA
genes in the E. coli K12 genome. Using the BlastP algo-
rithm [37] for comparison of E. coli K12 proteins with
human protein equivalents, E. coli proteins with highest
homologies to human proteins were identified. LUCA
proteins were excluded from this list. Thus, 48 ECHH pro-
teins with highest homologies to human proteins and not
represented in the LUCA set of proteins were identified.
Construction of vectors
Expression vector pQTEV2
pQTEV2 (Fig 6) [GenBank:EF429248] was derived from
pQTEV [30]. A DNA fragment with EcoRI and HindIII
overhangs and coding sequences of His7-tag, Gateway attB
recombination sites, and TEV protease site was cloned
directionally into pQTEV. The expression vector pQTEV2
was propagated in electro-competent E. coli XL1-blue cells
and the correct DNA sequence was verified by DNA
sequencing.
Gateway destination vectors pD-GEX1, pD-MAL1, and pD-Nus1
Destination vector pD-GEX1 [GenBank:EF431916] was
derived from vector pGEX-5X-1 (GE healthcare). A DNA
fragment with BamHI and NotI overhangs and coding
sequences for the His7-tag and the SmaI restriction site
was cloned directionally into pGEX-5X-1 (5'-BamHI-CAT-
CACCATCACCATCACCATTCCCGGGC-NotI-3'). The
resulting vector was digested with SmaI, followed by the
ligation with the Gateway cassette RfC.1 to clone pD-
GEX1.
Features of expression vector pQTEV2 Figure 6
Features of expression vector pQTEV2. The vector 
was used for expression of His7-tagged proteins. Due to the 
presence of attB1/2 sites, pQTEV2 is suitable for Gateway 
recombination cloning.Microbial Cell Factories 2007, 6:18 http://www.microbialcellfactories.com/content/6/1/18
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Destination vector pD-Mal1 [GenBank:EF431917] was
derived from pMAL-c2X (NEB). A DNA fragment with
SacI and HindIII overhangs and coding sequences for the
His7-tag and the SmaI restriction site was cloned direc-
tionally into pMAL-c2X (5'-SacI-CGCATCACCATCAC-
CATCACCATTCCCGGGA-HindIII-3'). The vector was
digested with SmaI, followed by ligation-cloning of Gate-
way cassette RfC.1 into the vector.
Destination vector pD-Nus1 [GenBank:EF431918] was
derived from pET-44a (Novagen). Vector pET-44a was
digested with SacII and XhoI. The overhangs were
removed by treatment with T4 DNA polymerase (NEB),
followed by ligation-cloning of Gateway cassette RfA into
the vector. Note that this vector encodes two His6-tags.
All destination vectors were propagated in chemically
competent E. coli DB3.1 cells. Correct DNA sequences of
the destination vectors were verified by DNA sequencing.
Expression of proteins in pD-Mal1, pD-GEX1, or pD-
Nus1 resulted in MBP-His7-tagged, GST-His7-tagged, or
NusA-His6-tagged fusion proteins, respectively.
E. coli host strains
Competent  E. coli cells were prepared with CaCl2 and
MnCl2 as described previously [38]. The competent cells
were frozen in liquid nitrogen and stored at -80°C. Elec-
tro-competent E. coli cells were prepared as described pre-
viously [39]. The competent cells were frozen in liquid
nitrogen and stored at -80°C.
Cloning of E. coli K12 genes into pQTEV2
Our standard procedure employed PCR cloning of E. coli
genes [30] into pQTEV2 (Fig 6) using restriction sites
BamHI and NotI and a genomic DNA preparation from E.
coli K12 from the German strain collection (DSMZ 5695).
In case of intragenic BamHI sites, this enzyme was
replaced by BglII. A second choice was use of type II
enzymes BpiI or Eco31I. PCR primers were delivered in
96-well microplate format (Eurogentec). 10 μM stocks of
forward and reverse PCR primers were rearranged by a
Speedy pipetting robot (Zinsser) in corresponding plate
positions of two polystyrene microtitre plates [30]. PCR
reactions were performed with Expand High Fidelity PCR
kit (Roche Applied Science) according to the manufac-
turer's instructions. The PCR products were analyzed and
quantified by agarose gel electrophoresis. Subsequently,
the PCR products were purified with magnetic beads
(Genopure ds kit, Bruker) according to the manufacturer's
instructions. The PCR products were digested o/n with
restriction enzymes with 10 units of each enzyme per reac-
tion. After an additional purification step with magnetic
beads, ligation reactions were set up taking into account
visual estimates of PCR product concentrations. PCR
product and water were added to make 6.5 μl in a well of
a Thermowell 96-well plate, followed by the addition of 2
μl of linearized pQTEV2 (16 ng), 0.5 μl T4 DNA ligase
(400 units/μl, NEB), and 1 μl 10× ligase buffer (NEB). The
plate was covered with a sealing sheet and the samples
were incubated at 20°C for 1 h, followed by heat inactiva-
tion (65°C, 20 min). Chemically competent E. coli SCS1
cells [30] were transformed with 5 μl of the ligation reac-
tion in a Thermowell 96-well plate using standard heat
shock procedure (42°C, 45 sec). Cells were recovered for
30 min at 37°C with 1 ml of 2xYT broth [16], supple-
mented with 20 mM MgCl2 and 20 mM glucose. The cul-
tures were plated on individual 2xYT agar plates,
containing 100 μl/ml ampicillin and were incubated o/n
at 37°C. Six colonies per transformation were picked with
sterile tooth picks into individual wells of a polystyrene
microtitre plate, containing 200 μl of stock medium: 2xYT
broth, 1xHMFM, 100 μl/ml ampicillin, and 2% glucose
(10xHMFM: solution "a": 5 mM MgSO4.4H20, 20 mM tri-
Sodium citrate.2H2O, 85 mM (NH4)2SO4, 45% glycerol;
solution "b": 0.66 M KH2PO4, 1.3 M K2HPO4; four parts
of solution "a" were combined with one part of solution
"b"). The plate was incubated o/n at 37°C, sealed and
stored at -80°C. To identify successfully cloned inserts, 6
clones per transformation were screened by colony PCR
with primers pQE65 (5'-TGAGCGGATAACAATT-
TCACACAG-3') and pQE276 (5'-GGCAACCGAGCGT-
TCTGAAC-3') which bind to internal vector sequences
adjacent to the multiple cloning site. After analysis of the
PCR reactions on agarose gels, two positive clones per
transformation were sub-cultured for protein expression
in individual wells of a polystyrene microtitre plate, con-
taining 200 μl of stock medium.
Gateway cloning
We utilized the Gateway (Invitrogen) recombination tech-
nology [40] to fuse the target protein with fusion partners,
such as MBP, GST, or NusA. These fusion partners may
enhance solubility of target proteins [32]. We therefore
constructed three Gateway destination vectors for expres-
sion of target proteins fused to MBP-His7, GST-His7, and
NusA-His6 (pD-MAL1, pD-GEX1, and pD-Nus1, respec-
tively). All three destination vectors contained the
sequence coding for a His-tag, enabling purification of
either protein fusion by His-tag affinity to Ni-NTA agar-
ose. In order to create entry clones, we performed BP
recombination reactions between pQTEV2 containing the
gene of interest and the Gateway donor vector
pDONR221, followed by the transformation of E. coli
XL1-blue cells, according to the manufacturer's instruc-
tions (Invitrogen). Positive entry clones were confirmed
by colony PCR screening with primers M13Forward and
M13Reverse which bind to internal vector sequences adja-
cent to the att sites. In the LR reaction, plasmid prepara-
tions of entry clones were incubated with the destination
vectors pD-MAL1, pD-GEX1, and pD-Nus1, respectively,Microbial Cell Factories 2007, 6:18 http://www.microbialcellfactories.com/content/6/1/18
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in order to generate E. coli SCS1 expression clones for
MBP-His7 or GST-His7 fusion proteins. Electro-competent
E. coli BL21 (DE3) cells were transformed with LR reac-
tions of pD-Nus1. Positive expression clones were con-
firmed by colony PCR screening. pD-MAL1 constructs
were screened with primers M13Forward (5'-Gcggatcctac-
ctgacgcttt-3') and malE (5'-GGTCGTCAGACTGTCGAT-
GAAGCC-3'). pD-GEX1 constructs were screened with
primers pGEX5' (5'-GGGCTGGCAAGCCACGTTTGGTG-
3') and pGEX3' (5'-CCGGGAGCTGCATGTGTCAGAGG-
3'). pD-Nus1 constructs were screened with primers Nus-
tag (5'-AAGCCGGAGCACTGATTATGG-3') and Colidown
(5'-TTCACTTCTGAGTTCGGCATGG-3').
Characterization of expression clones by small-scale 
protein expression and purification
To identify clones that provided sufficient amounts of
His-tagged proteins, small-scale expression and purifica-
tion was performed as described previously [16]. Protein
expression was induced with 1 mM IPTG at 25°C for 6 hrs
and at 37°C for 3 hrs. Overexpression of the recombinant
protein was analyzed in the cell lysate. Purification under
native conditions via affinity chromatography with Ni-
NTA agarose (Qiagen) was performed to assess yields of
purified proteins. Cell lysates and purified proteins were
analyzed by SDS-PAGE with 15% polyacrylamide separa-
tion gels as described [41]. Expression levels in cell lysates
and yields of purified proteins were subjectively attributed
to one of four categories: 3 (high), 2 (moderate), 1 (low),
0 (not purified).
Large-scale protein expression and purification
According to protein yields obtained after small-scale
expression and purification, culture volumes were
adjusted for large-scale expression and purification. Pro-
teins that were purified in high and moderate yields were
expressed in 100 ml or 150 ml cultures, respectively. The
following expression and purification protocol was
applied per 100 ml of bacterial culture: 5 ml pre-culture
was grown for 16 hrs at 37°C, followed by the addition of
95 ml of pre-warmed SB medium with ampicillin [16]. At
the optical density (OD) of 1.5 at 600 nm, protein expres-
sion was induced for 4 hrs at 37°C with 1 mM IPTG or 6
hrs at 25°C. Cells were harvested by centrifugation (4000
× g, 4°C, 15 min) in 50 ml polypropylene tubes (BD Fal-
con). The cell pellet was frozen in liquid nitrogen and
stored at -80°C. To purify protein, the cell pellet was
thawed on ice for 15 min and resuspended in 3 ml of lysis
buffer [16]. 450 μl of lysozyme solution (1 mg/ml) was
added and incubated on ice for 30 min. 600 μl of benzo-
nase buffer (20 mM Tris, pH 8.0, 10 mM MgCl2) contain-
ing 0.4 unit/μl benzonase grade II (Merck) was added and
incubated on ice for 30 min. The lysate was centrifuged at
4900 × g, 4°C, 45 min. The supernatant was transferred to
individual cavities of a 24-deepwell plate (Brand) and 600
μl of 50% Ni-NTA agarose (Qiagen) was added. The plate
was shaken for 30 min at 10°C and the lysate-bead mix-
ture was transferred to a well of a 96-well filter plate
(Macherey & Nagel, No 738655.M). Ni-NTA agarose was
washed 6 times with 1.5 ml of washing buffer. Protein was
eluted with 600 μl of elution buffer [16]. EDTA (final con-
centration: 0.5 mM) was added to bind residual Ni2+ ions
in the protein solution. In order to exchange the buffer,
500 μl of the protein solution was applied on a NAP-5 col-
umn (GE healthcare) and the protein was eluted with 1 ml
of phosphate buffered saline (PBS, pH 7.4).
LPS removal with polymyxin B coated magnetic beads
After changing the buffer, we treated the protein solutions
with polymyxin B coated magnetic beads (25 mg/ml;
Chemicell, Berlin, Germany) in order to remove LPS. Per
protein, 10 mg of LPS removal beads were transferred into
1.5 ml reaction tubes (Eppendorf) and washed three times
with 1 ml PBS. To bind LPS, protein solutions were added
to the beads and mixed constantly for 30 min at 4°C.
Afterwards, the tubes were placed in a magnet and the
cleared protein solutions were transferred into fresh reac-
tion tubes.
Sterilization of protein solutions
Protein solutions were filtered with 0.2 μm syringe filters
(Pall). Protein concentrations were determined by photo-
metric determination of the OD at 280 nm. In case of pro-
tein loss during downstream applications, such as buffer
exchange and LPS removal, proteins were expressed in
larger volumes (1–2 l).
Whole blood stimulations with protein preparations
Aliquots of protein solutions 98, 251, 253, and 256 (see
additional file 1: SummaryOfResults.xls) were treated
with LPS removal beads. Treated and untreated protein
preparations were used for whole blood stimulations as
described previously [42]. Per ml of blood, 5 μg of protein
was used. Fixed and permeabilized cells were stained with
following antibodies (BD): CD4-peridinin chlorophyll A
protein (PerCP), CD154 (CD40 Ligand)-phycoerythrin
(PE), IFN-γ-allophycocyanin (APC). Cells were analyzed
using a FACScalibur flow cytometer and Cell Quest soft-
ware (both BD). CD4+ T cells were gated electronically
and were quantified as the frequencies of cells that were
double-positive for CD40 Ligand (CD40L) and IFN-γ. Fre-
quencies resulting from stimulations with treated proteins
vs. untreated proteins were related to each other. CD40L
was shown to be a universal marker for activation of anti-
gen-specific CD4+ T cells [42]. We used CD40L up-regula-
tion as a marker for T cell activation upon stimulation
with our recombinant E. coli proteins.Microbial Cell Factories 2007, 6:18 http://www.microbialcellfactories.com/content/6/1/18
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LAL test
Proteins 251 and 96 were treated with polymyxin B beads
and LPS contents in the protein solutions were quantified
with the Limulus amoebocyte lysate (LAL) test by Profos
(Regensburg, Germany).
Analyses of codon usage and prediction of transmembrane 
helices
CAI values [25] were determined using the EMBOSS soft-
ware package (4.0.0) and the codon usage file
Eecoli_high.cut [43]; the number of rare codons was
established using the NIH Rare Codon Calculator [44]; for
prediction of transmembrane helices we used the CBS pre-
diction server TMHMM (2.0) [45].
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